Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity (Cell Metabolism)

Using metabolically focused CRISPR/Cas9 loss-of-function screens, Lin and Xie et al. map the metabolic-apoptotic interface in AML, revealing metabolic pathways that can be therapeutically targeted to augment chemotherapy. In particular, the authors identify heme biosynthesis as an actionable pathway whose prognostic importance is supported by clinical omics data.